May 17th 2024
Tarlatamab — now with the brand name Imdelltra — is the first approved bispecific antibody for a solid tumor.
Otsuka, Lundbeck Submit sNDA for Rexulti in Adolescents with Schizophrenia
October 15th 2021Submission is based on extrapolation analysis and results examining the effects of Rexulti in treating symptoms of schizophrenia in patients 13 to 17 years old. The FDA is expected to complete its review in December 2021.